IgE and Mast Cells: The Cell Is Armed in Advance

The mast cell is loaded long before the allergen arrives. IgE bound to FcεRIα is not waiting to be recruited the way an antibody waits for antigen in a serum assay — it is already installed on the cell surface, at saturating occupancy, with a half-life measured in weeks rather than the two days free IgE survives in plasma. That single fact reorganises how you should think about the whole of type 2 immunity. The sensitising event and the challenge event are separated in time, the cell is pre-armed, and what determines the size of the response is how many receptors carry allergen-specific IgE and how densely the allergen can crosslink them. Antigen dose barely features.

Type 2 immunity from epithelial alarmin to mast-cell mediator and tissue remodelling. Open the interactive version to click any protein for its role and the matching validated reagent.

The epithelium decides before any lymphocyte does

Type 2 responses are usually drawn starting at the T cell, which puts the decision one step too late. The three alarmins — TSLP, IL-33 and IL-25 — are released by damaged or stressed barrier epithelium, and they set the polarising context before an antigen-specific cell has seen anything. They are not interchangeable. IL-33 is stored pre-formed in the nucleus of healthy epithelial and endothelial cells and released as an alarmin on necrosis, acting through ST2 (IL1RL1); TSLP is transcribed and secreted, acting through TSLPR/CRLF2 to license dendritic cells; IL-25 comes largely from tuft cells and drives ILC2 expansion. That distinction is why anti-TSLP and anti-IL-5 behave differently in severe asthma: one is acting upstream of the polarisation decision, the other downstream on a single effector arm.

This is also the practical reason so many type 2 models fail to reproduce. If your protocol involves an epithelial insult — papain, a protease-containing allergen, mechanical damage — the alarmin axis is doing work you have not accounted for, and it will run with or without a cognate T-cell response.

Th2 commitment: one cytokine, one STAT, one transcription factor

The polarisation circuit itself is unusually clean. IL-4 engages IL-4Rα on a naive CD4 T cell, which phosphorylates STAT6, which induces GATA-3, which opens the type 2 cytokine locus and reinforces its own expression. It is a feed-forward loop with IL-4 as both the input and one of the outputs, which is why type 2 responses are so hard to stop once they are established and why the initial source of IL-4 — basophils, ILC2s, the mast cell itself — matters far more than its abundance later.

The receptor detail is worth having straight, because it explains a widely used drug. IL-4Rα is shared between the type I receptor (IL-4Rα + γc, IL-4 only) and the type II receptor (IL-4Rα + IL-13Rα1, which both IL-4 and IL-13 use). Blocking IL-4Rα therefore removes IL-4 and IL-13 signalling together, which is precisely why targeting the shared chain outperforms blocking either cytokine alone in atopic dermatitis. It is a good example of a pathway where the receptor, not the ligand, is the right node.

The four output cytokines do different jobs

IL-4 drives the isotype switch and sustains the loop. IL-5 is almost purely an eosinophil cytokine — survival, maturation and release from marrow, through IL-5Rα. IL-13 does the tissue work: goblet-cell metaplasia and MUC5AC secretion, smooth-muscle hyperresponsiveness, and fibroblast periostin production. IL-9 supports mast-cell expansion in tissue, and amphiregulin is the repair arm — a reminder that this whole programme evolved for barrier repair and helminth expulsion, not for making people miserable in spring.

Two IgE receptors that do opposite things

The class switch to IgE needs both IL-4 or IL-13 and a CD40 signal from the T cell, and it happens in a CD19-positive B cell that will go on to secrete very little antibody by mass. Total serum IgE is on the order of a thousand-fold lower than IgG, and yet it dominates the response, because the receptor does the amplification rather than the antibody.

FcεRI is the high-affinity receptor, K_D around 10^-10 M, expressed on mast cells and basophils as a tetramer whose FcRγ chains carry the ITAMs. At that affinity it is occupied at physiological IgE concentrations, so the receptor is functionally a permanent IgE-display platform. Crosslinking two or more of them recruits SYK and the cell degranulates within seconds.

CD23 (FcεRII) is the low-affinity receptor and is a different kind of protein entirely — a C-type lectin, not an immunoglobulin-superfamily member, on B cells and epithelium. It does facilitated antigen presentation and negative feedback on IgE production. Grouping the two together as "IgE receptors" hides the fact that one amplifies the response and the other restrains it. For allergen-specific work, OVA-specific IgE is the readout that tracks the sensitising event; total IgE moves for many reasons that have nothing to do with your antigen.

Degranulation, and the mediators that arrive in three waves

Mast cells depend on SCF through c-Kit for survival and tissue residency, which is separate from the activation signal and is why c-Kit inhibition depletes the cells rather than silencing them. When crosslinked FcεRI recruits SYK, the output comes in three temporally distinct waves. Pre-formed granule contents first: histamine and tryptase within seconds to minutes. Then newly synthesised lipid mediators — LTC4 synthase generating cysteinyl leukotrienes over minutes. Then cytokines and chemokines over hours.

Choosing the wrong wave for your timepoint is a common and avoidable error. Histamine peaks and clears fast; tryptase is the stable marker of mast-cell activation and is what clinical anaphylaxis testing uses for exactly that reason. If you sample at four hours you will see the cytokine wave and conclude nothing happened acutely.

Recruiting the eosinophil

Eotaxin-1/CCL11 acting on CCR3 is the chemotactic axis, and IL-5 through IL-5Rα supplies the cells to be recruited. Two further receptors are worth having on the map: CRTH2 (DP2), the prostaglandin D2 receptor that links mast-cell activation directly to Th2 and eosinophil chemotaxis, and Siglec-8, an inhibitory receptor restricted to eosinophils and mast cells whose engagement induces eosinophil apoptosis — the target logic behind lirentelimab and a useful reminder that this system has built-in off switches.

The regulatory arm you should not leave out

Type 2 responses are restrained, and models that ignore the restraint tend to over-read their own effect sizes. CD25-high regulatory T cells and IL-10 are the two nodes that matter most here. IL-10 in particular is the mechanism behind successful allergen immunotherapy: the clinical benefit correlates with induction of IL-10-producing regulatory cells and a shift in the IgG4-to-IgE ratio, not with removal of IgE. If your intervention shrinks a type 2 response, the informative question is whether it blocked an effector arm or engaged the regulatory one, and the two have very different implications for durability.

Designing the experiment: what to block and what to measure

A note on the reagents

Six nodes on this map carry In Vivo functional-grade antibodies — CD4, IL-4, CD40, CD19, CD25 and IL-10 — all low or ultra-low endotoxin, which matters here because endotoxin pushes a response towards type 1 and will quietly work against the very phenotype you are trying to induce. Three further nodes (IL-4Rα, IL-5 and IL-13) link to research-grade biosimilars of the corresponding clinical antibodies rather than to functional-grade in vivo formats; they are the right tool for binding and detection work, not for blocking studies in animals. Everything else on the map is an ELISA, and for a pathway this cytokine- and mediator-driven, that is usually what you actually need.

The short version

Barrier epithelium sets the direction with TSLP, IL-33 and IL-25 before any lymphocyte commits. IL-4 to STAT6 to GATA-3 is a self-reinforcing loop, so the first source of IL-4 matters more than the total. IL-4Rα is shared between two receptor complexes, which is why blocking the chain beats blocking either cytokine. The mast cell is pre-armed through high-affinity FcεRI and responds to crosslinking density rather than dose, releasing its mediators in three waves that need three different sampling times. And there is a regulatory arm — CD25 and IL-10 — that determines whether anything you do to this system lasts.

For the B-cell side of the switch and the antibody that results, see the B-cell activation and germinal centre map; for the opposing T-helper programmes, see Th17 cells and the IL-23 axis.

For research use only. Not for use in diagnostic or therapeutic procedures.